

### Study Number

16 weeks

24 weeks


52 weeks 104 weeks

7.6 years

Maximum individual exposure

Pre-Registration Studies

Post-Registration Studies



Placebo

CZP 100 mg Q2W<sup>#</sup>

CZP 200 mg Q2W

CZP 400 mg Q2W<sup>†</sup>CZP 400 mg Q4W<sup>\*</sup>

CZP 200 mg Q4W

ADA 40 mg Q2W

Open-label CZP

Open-label DMARDs only



Mandatory escape to OLE for CZP and PBO-treated pts who did not achieve ACR20 (RAPID 1 & 2, J-RAPID and HIKARI), or CDAI  $\leq 2.8$  (CERTAIN). Mandatory treatment switch at Week 12 for patients who did not achieve DAS28-ESR  $\leq 3.2$  or a DAS28-ESR reduction from baseline of  $\geq 1.2$  (EXXELERATE).



Patients who flared (CDAI  $\geq 11$ ) on DMARDs between Weeks 24 and 52 during CERTAIN were allowed to enter the OLE on CZP 200 mg Q2W after a 400 mg Q2W loading regimen (3 doses). Patients on PBO in C-EARLY Period 2 who flared (with an increase in DAS28-ESR  $\geq 0.6$  above that at Week 52,  $>3.2$  plus an investigator-judged increase in RA activity, all for 2 consecutive visits), between Weeks 52 and 104 entered treatment with CZP 200 mg Q2W following loading.



Patients who completed the RCT period and subsequently entered the OLE



Patients who withdrew prior to completion of the RCT and subsequently entered the OLE

\*\*Followed by long-term open-label extension